Small Biotech Innovation Act

The Small Biotech Innovation Act (HR3731) was introduced on June 4, 2025, by Rep. Pfluger (R-TX) and referred to the Energy and Commerce and Ways and Means Committees. The bill has 3 cosponsors and an identical companion bill in the Senate (S1930), but has seen no action since referral — indicating low legislative velocity. The bill amends the Social Security Act to create a narrow exception: manufacturers with 5 or fewer qualifying single-source drugs that are R&D-intensive would avoid having their drugs selected for Medicare price negotiation under the Inflation Reduction Act's program, starting in 2029. There is no funding authorization or appropriation in this bill — it is a regulatory exemption with zero direct federal spending. The money trail is indirect: exempted drugs would retain pricing flexibility against Medicare, preserving higher revenue streams than if they were subject to negotiation. The Congressional Budget Office (CBO) would likely score this as a net cost to the federal government (foregone savings from negotiation), not a funding allocation. Structural winners would be small, R&D-focused biotech firms with limited marketed products but significant pipeline value — names like $MRNA (Moderna), $BIIB (Biogen), and $ALNY (Alnylam) could qualify. Large-cap biotechs with broad portfolios (e.g., $AMGN, $GILD) would not qualify. However, the bill is in its earliest stage — it has not been marked up, debated, or voted on. The 119th Congress has over a year remaining, but the bill faces a crowded healthcare legislative calendar and bipartisan skepticism of IRA drug pricing carve-outs. No real market data was provided in the enrichment for biotech stock performance. Based on bill structure alone, there is no near-term market impact. The exemption, if passed, would affect Medicare negotiation cycles starting in 2029 — a 3-year forward horizon that has zero near-term revenue implications for any company. The bill's legislative timeline: it must pass both House committees (Energy & Commerce, Ways & Means), then the full House, then the Senate (with companion S1930), and be signed by the President. With no committee hearings or markups recorded in 10 months, this bill is stalled. Investors should monitor for (1) a hearing announcement, (2) inclusion in a larger healthcare package, or (3) cosponsor additions that signal momentum.